Impellam Group plc

Impellam Group plc provides staffing solutions, human capital management, and outsourced people-related services in the United Kingdom, North America, rest of Europe, and Australasia. It operates through four segments: Global Managed Services, STEM, Regional Specialist Staffing, and Healthcare. The Global Managed Services segment engages in the design, implement, coordinate, and report on the talent acquisition process through the provision of multi-disciplinary outsourced recruitment services under the Comensura, Guidant Global, and Flexy brand names. The STEM provides specialist contract and permanent recruitment services of scientists, clinicians, engineers, IT, and digital specialists under the Lorien, Carbon60, Bartech, and SRG brand names. The Regional Specialist Staffing segment offers staffing services for warehouse workers, secretaries, call centre operatives, lawyers, drivers, teachers, chefs, and HR and marketing professionals under the Blue Arrow, Tate, Career Teacher, and Chadwick Nott brand names. The Healthcare segment provides healthcare workforce solutions, including healthcare staffing, managed services, staff bank, occupational health, insourcing, social care, and home care services under the Medacs Healthcare, Global Medics, and Litmus Workforce Solutions brand names. This segment also recruits locum, temporary and permanent doctors, nurses, care workers, and allied health professionals. The company was incorporated in 2008 and is based in Luton, the United Kingdom.

Impellam Group plc trades as IGPPF on OTC. The company is classified in Industrials / Staffing & Employment Services and reports in USD.

The current profile places the business in Staffing & Employment Services. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $1.96B of revenue and $16.80M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Impellam Group plc can be compared against peers such as AMAYA Global Holdings Corp., bpost NV/SA, China Aircraft Leasing Group Holdings Limited, Capita plc, Hyve Group Plc, Marlowe plc.

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $498.22M, beta of 0.41, and return on equity of +7.4%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

IGPPF currently shows total debt of $87.70M and beta of 0.41. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.impellam.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.